TScan pauses Phase 3 trial, focusing on solid tumor in vivo TCR-T therapy
TScan Therapeutics paused its Phase 3 ALLOHA-2 study due to capital constraints and reorganized to prioritize advancing in vivo-engineered TCR-T candidates for solid tumors, amid maintaining cash runway into Q4 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed